Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies
Reads0
Chats0
TLDR
A series of monoclonal antibodies that reacts with myeloids-associated determinants on committed myeloid stem cells and their progeny are generated and potential applications of these antibodies to studies of normal and malignant hematopoiesis are discussed.About:
This article is published in Blood.The article was published on 1983-07-01 and is currently open access. It has received 268 citations till now. The article focuses on the topics: Myeloid stem cell & Monoclonal antibody.read more
Citations
More filters
Journal Article
Approval Summary: Gemtuzumab Ozogamicin in Relapsed Acute Myeloid Leukemia
Peter F. Bross,Julie Beitz,Gang Chen,Xiao Hong Chen,Eric Duffy,Lydia Kieffer,S K Roy,Rajeshwari Sridhara,Atiqur Rahman,Grant R. Williams,Richard Pazdur +10 more
TL;DR: Tolerability and ease of administration may be improved compared with conventional chemotherapy, except for hepatotoxicity, with 31% of patients exhibiting abnormal liver enzymes, and the reduction of leukocyte counts to below 30,000/ml is recommended prior to treatment.
Journal Article
Chimeric Receptors Providing Both Primary and Costimulatory Signaling in T Cells from a Single Gene Product
TL;DR: These constructs represent the first of a new generation of single gene multidomain chimeric receptors capable of mediating both primary and costimulatory signaling specifically from a single extracellular recognition event.
Journal ArticleDOI
Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain.
TL;DR: This type of chimeric receptor may now be used to discover the most potent combination of costimulatory signals that will improve current immunotherapeutic strategies.
Journal ArticleDOI
Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate.
Eric L. Sievers,F R Appelbaum,R.T. Spielberger,Stephen J. Forman,David A. Flowers,Franklin O. Smith,K. Shannon-Dorcy,Mark S. Berger,Irwin D. Bernstein +8 more
TL;DR: In a dose escalation study, 40 patients with relapsed or refractory CD33 + acute myeloid leukemia (AML) were treated with an immunoconjugate (CMA-676) consisting of humanized anti-CD33 antibody linked to the potent antitumor antibiotic calicheamicin this paper.
Journal ArticleDOI
A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells
TL;DR: Anti-MY9 may be a valuable reagent for the purification of hematopoietic colony-forming cells and for the diagnosis of myeloid-lineage leukemias.
References
More filters
Journal ArticleDOI
Continuous cultures of fused cells secreting antibody of predefined specificity
G Köhler,C. Milstein +1 more
TL;DR: The derivation of a number of tissue culture cell lines which secrete anti-sheep red blood cell (SRBC) antibodies is described here, made by fusion of a mouse myeloma and mouse spleen cells from an immunised donor.
Journal ArticleDOI
Glycosphingolipids in Cellular Interaction, Differentiation, and Oncogenesis
TL;DR: The majority of neutral glycolipids present in plasma membranes are cryptic, and further extensive studies of the organization of glycolIPid in other eukaryotic cell membranes are necessary.
Journal Article
A monoclonal antibody reactive with human peripheral blood monocytes.
TL;DR: Findings provided additional support for the notion that OKM1 was reactive with monocytes, and appeared to define two distinct populations of monocytes; an adherent population of large cells bearing surface Ia determinants and a nonadherent population of small, Ia-negative cells.
Journal Article
Antigens on human monocytes identified by monoclonal antibodies.
TL;DR: Results indicate that Mo1 and Mo2 are unique antigens that may represent distinct stages of late monocyte-granulocyte differentiation.
Journal ArticleDOI
Expression of myeloid differentiation antigens on normal and malignant myeloid cells.
TL;DR: A series of monoclonal antibodies have been characterized that define four surface antigens (MY3, MY4, MY7, and MY8) of human myeloid cells derived from a fusion of the NS-1 plasmacytoma cell line with splenocytes from a mouse immunized with human acute myelomonocytic leukemia cells.